Dupixent EOE denied as experimental or investigational by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for dupixent eoe are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Denied Dupixent for Eosinophilic Esophagitis as Experimental

An experimental or investigational denial for Dupixent (dupilumab) in eosinophilic esophagitis (EoE) means UnitedHealthcare determined that the therapy does not meet its evidentiary standard for established clinical benefit in this indication. This type of denial often emerges from coverage policies that have not been updated to reflect a subsequent FDA approval, or from policies that apply the approved indication more narrowly than the label supports.

The FDA granted dupilumab approval for EoE, making a straightforward experimental denial particularly vulnerable to appeal and external review. The external IRO process — where a reviewer independent of UHC applies objective evidence standards — is your most powerful tool for this denial type.

## Federal Appeal Rights

• ACA §2719 explicitly requires non-grandfathered plans to allow external IRO review for experimental/investigational denials. This is the strongest federal protection available for this denial type — use it.
• ERISA §503 guarantees full-and-fair internal review with written clinical rationale for employer-sponsored plans.
• Internal appeal: typically 180 days from denial notice.
• External review: typically 4 months from final internal denial.
• Expedited review: available when standard timelines would seriously jeopardize your health — request in writing with prescriber documentation of urgency.

## Step 1: Establish FDA Approval Status

Obtain the current FDA-approved prescribing label for dupilumab (available at FDA.gov). Identify the EoE indication section. Compare the label's approved population criteria to your chart documentation. If your clinical presentation aligns with the approved indication, the "experimental" characterization is directly contradicted by FDA action and your appeal should lead with this.

## What to Gather

1. FDA prescribing label — the current approved label with the EoE indication highlighted. Note the FDA approval date and compare it to the date of UHC's coverage policy. 2. Endoscopy and biopsy reports — confirming EoE diagnosis with eosinophil counts per high-power field from pathology. This establishes you within the defined patient population. 3. Symptom burden documentation — chart notes documenting dysphagia frequency and severity, food impaction events, quality-of-life impact, and response (or lack thereof) to prior standard therapies. 4. Prior treatment history — documentation of dietary elimination trials, swallowed topical corticosteroid use with dates and outcomes, and any other standard EoE therapies tried. 5. Prescriber medical-necessity letter — your gastroenterologist should state that (a) your diagnosis falls within the FDA-approved indication, (b) the use is not experimental but regulatory-approved, (c) prior standard therapies have been inadequate, and (d) applicable guideline organization recommendations (e.g., American College of Gastroenterology, American Gastroenterological Association) support this use. 6. UHC's coverage policy — identify the effective date and the evidentiary standard applied. If the policy predates FDA approval or mischaracterizes the approved population, note this discrepancy explicitly.

## Criteria-Mapping Structure

| UHC Experimental Finding | Your Response | |---|---| | Insufficient evidence of benefit | FDA approval for EoE exists — cite label date and indication text | | Patient outside studied population | Prescriber attestation that chart findings match FDA-approved population | | Policy predates regulatory action | Note UHC policy date vs. FDA EoE approval date | | No guideline support | Reference applicable GI society guideline organization support |

If the internal appeal is denied, proceed immediately to IRO external review. IRO decisions are binding on UHC and are issued by reviewers who apply objective evidence standards rather than UHC's internal policy criteria.